GlassScriptPhysician profile
Mohsen Ghafouri
NPI 1912929233
$14,045.54
in general payments reported to CMS, 2019-2025
36 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,668 · 2020: $1,576 · 2021: $3,191 · 2022: $1,440 · 2023: $1,391 · 2024: $1,132 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.15 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,398.73 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,133.64 | 2019-2025 | |
| Amgen INC. | $2,088.07 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Novartis Pharmaceuticals Corporation | $1,109.70 | 2019-2025 | |
| Pfizer INC. | $1,029.97 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $1,014.07 | 2020-2025 | Acthar |
| Ucb, INC. | $765.28 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $564.33 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $507.30 | 2019-2024 | Benlysta, Nucala |
| Mallinckrodt Enterprises LLC | $388.20 | 2019 | |
| Lilly USA, LLC | $283.89 | 2019-2024 | Taltz |
| Celgene Corporation | $263.97 | 2019 | |
| Genentech USA, INC. | $243.35 | 2019-2024 | Actemra |
| Ani Pharmaceuticals, INC. | $156.92 | 2023-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $130.25 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $114.16 | 2019-2023 | Tymlos |
| Alexion Pharmaceuticals, INC. | $113.00 | 2022-2024 | Strensiq |
| Horizon Therapeutics Plc | $110.67 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $81.73 | 2023-2024 | Idacio |
| Aurinia Pharma U.S., INC. | $69.94 | 2022-2024 | Lupkynis |
| Edwards Lifesciences Corporation | $65.47 | 2019 | |
| Sobi, INC | $60.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $56.63 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $50.92 | 2021-2022 | |
| Depuy Synthes Sales INC. | $30.47 | 2024 | Orthovisc, Peak, Monovisc |
| Kyowa Kirin, INC. | $24.34 | 2023 | Crysvita |
| Merck Sharp & Dohme LLC | $23.97 | 2019 | |
| Sandoz INC. | $23.96 | 2025 | Hyrimoz |
| Organon LLC | $23.42 | 2025 | Renflexis, Hadlima |
| Fidia Pharma USA INC. | $23.40 | 2022 | |
| Pacira Therapeutics, INC. | $21.90 | 2019 | |
| Tonix Medicines, INC. | $21.83 | 2025 | Tonmya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.47 | 2024 | Ofev |
| Zyla Life Sciences, INC. | $15.05 | 2019 | |
| Genzyme Corporation | $14.98 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Ghafouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.